{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T20:13:36Z","timestamp":1785615216868,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Sino-German Mobility Programme","award":["M-0670"],"award-info":[{"award-number":["M-0670"]}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"crossref","award":["BE2020622"],"award-info":[{"award-number":["BE2020622"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82273301"],"award-info":[{"award-number":["82273301"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018541","name":"Natural Science Foundation of Jiangsu Province for Distinguished Young Scholars","doi-asserted-by":"crossref","award":["BK20240018"],"award-info":[{"award-number":["BK20240018"]}],"id":[{"id":"10.13039\/501100018541","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Nanjing Health Technology Development, Project Foundation for Distinguished Young Scholars","award":["JQX23001"],"award-info":[{"award-number":["JQX23001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06460-8","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:12:47Z","timestamp":1778519567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Olaparib combined with abiraterone in HRR-mutated metastatic hormone-sensitive prostate cancer: a single-arm phase II trial"],"prefix":"10.1007","volume":"44","author":[{"given":"Xuyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"6460_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"6460_CR2","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1200\/jco.2017.73.9987","volume":"35","author":"W Xie","year":"2017","unstructured":"Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O et al (2017) Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol 35:3097\u20133104. https:\/\/doi.org\/10.1200\/jco.2017.73.9987","journal-title":"J Clin Oncol"},{"key":"6460_CR3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/ju.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E et al (2023) Updates to advanced prostate cancer: AUA\/SUO Guideline. J Urol 209:1082\u20131090. https:\/\/doi.org\/10.1097\/ju.0000000000003452","journal-title":"J Urol"},{"key":"6460_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/s1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14:149\u2013158. https:\/\/doi.org\/10.1016\/s1470-2045(12)70560-0","journal-title":"Lancet Oncol"},{"key":"6460_CR5","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/jco.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A et al (2019) ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 37:2974\u20132986. https:\/\/doi.org\/10.1200\/jco.19.00799","journal-title":"J Clin Oncol"},{"key":"6460_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381:13\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1903307","journal-title":"N Engl J Med"},{"key":"6460_CR7","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","volume":"76","author":"AP Hoyle","year":"2019","unstructured":"Hoyle AP, Ali A, James ND, Cook A, Parker CC, de Bono JS et al (2019) Abiraterone in high- and low-risk metastatic hormone-sensitive prostate cancer. Eur Urol 76:719\u2013728. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.006","journal-title":"Eur Urol"},{"key":"6460_CR8","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.juro.2012.06.046","volume":"188","author":"CM Tangen","year":"2012","unstructured":"Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G et al (2012) Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 188:1164\u20131169. https:\/\/doi.org\/10.1016\/j.juro.2012.06.046","journal-title":"J Urol"},{"key":"6460_CR9","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1200\/jco.2010.34.3996","volume":"29","author":"IF Seruga BTannock","year":"2011","unstructured":"Seruga BTannock IF (2011) Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol 29:3686\u20133694. https:\/\/doi.org\/10.1200\/jco.2010.34.3996","journal-title":"J Clin Oncol"},{"key":"6460_CR10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H et al (2016) Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 375:443\u2013453. https:\/\/doi.org\/10.1056\/NEJMoa1603144","journal-title":"N Engl J Med"},{"key":"6460_CR11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/s1470-2045(19)30684-9","volume":"21","author":"J Mateo","year":"2020","unstructured":"Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R et al (2020) Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 21:162\u2013174. https:\/\/doi.org\/10.1016\/s1470-2045(19)30684-9","journal-title":"Lancet Oncol"},{"key":"6460_CR12","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1158\/1078-0432.Ccr-25-1178","volume":"31","author":"C Hage Chehade","year":"2025","unstructured":"Hage Chehade C, Graf RP, Ozay ZI, Gebrael G, Sayegh N, Li G et al (2025) Association of homologous recombination repair alterations with outcomes in patients with metastatic hormone-sensitive prostate cancer. Clin Cancer Res 31:4101\u20134109. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-25-1178","journal-title":"Clin Cancer Res"},{"key":"6460_CR13","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S et al (2020) Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382:2091\u20132102. https:\/\/doi.org\/10.1056\/NEJMoa1911440","journal-title":"N Engl J Med"},{"key":"6460_CR14","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1158\/2159-8290.Cd-12-0120","volume":"2","author":"MJ Schiewer","year":"2012","unstructured":"Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL et al (2012) Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov 2:1134\u20131149. https:\/\/doi.org\/10.1158\/2159-8290.Cd-12-0120","journal-title":"Cancer Discov"},{"key":"6460_CR15","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M et al (2018) Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379:2495\u20132505. https:\/\/doi.org\/10.1056\/NEJMoa1810858","journal-title":"N Engl J Med"},{"key":"6460_CR16","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, P\u00e9rol D, Gonz\u00e1lez-Mart\u00edn A, Berger R et al (2019) Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381:2416\u20132428. https:\/\/doi.org\/10.1056\/NEJMoa1911361","journal-title":"N Engl J Med"},{"key":"6460_CR17","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P et al (2021) Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 384:2394\u20132405. https:\/\/doi.org\/10.1056\/NEJMoa2105215","journal-title":"N Engl J Med"},{"key":"6460_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138\u2013148. https:\/\/doi.org\/10.1056\/NEJMoa1209096","journal-title":"N Engl J Med"},{"key":"6460_CR19","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352\u2013360. https:\/\/doi.org\/10.1056\/NEJMoa1704174","journal-title":"N Engl J Med"},{"key":"6460_CR20","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","volume":"35","author":"D Olmos","year":"2024","unstructured":"Olmos D, Lorente D, Alameda D, Cattrini C, Romero-Laorden N, Lozano R et al (2024) Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes. Ann Oncol 35:458\u2013472. https:\/\/doi.org\/10.1016\/j.annonc.2024.01.011","journal-title":"Ann Oncol"},{"key":"6460_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.clgc.2022.06.016","volume":"20","author":"AM Lee","year":"2022","unstructured":"Lee AM, Saidian A, Shaya J, Nonato T, Cabal A, Randall JM et al (2022) The prognostic significance of homologous recombination repair pathway alterations in metastatic hormone sensitive prostate cancer. Clin Genitourin Cancer 20:515\u2013523. https:\/\/doi.org\/10.1016\/j.clgc.2022.06.016","journal-title":"Clin Genitourin Cancer"},{"key":"6460_CR22","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.eururo.2018.01.035","volume":"74","author":"ES Antonarakis","year":"2018","unstructured":"Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y et al (2018) Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide. Eur Urol 74:218\u2013225. https:\/\/doi.org\/10.1016\/j.eururo.2018.01.035","journal-title":"Eur Urol"},{"key":"6460_CR23","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/jco.18.00358","volume":"37","author":"E Castro","year":"2019","unstructured":"Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J et al (2019) PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol 37:490\u2013503. https:\/\/doi.org\/10.1200\/jco.18.00358","journal-title":"J Clin Oncol"},{"key":"6460_CR24","doi-asserted-by":"publisher","first-page":"e1042","DOI":"10.1634\/theoncologist.2019-0495","volume":"25","author":"Y Wei","year":"2020","unstructured":"Wei Y, Wu J, Gu W, Wang J, Lin G, Qin X et al (2020) Prognostic value of germline DNA repair gene mutations in de novo metastatic and castration-sensitive prostate cancer. Oncologist 25:e1042\u2013e1050. https:\/\/doi.org\/10.1634\/theoncologist.2019-0495","journal-title":"Oncologist"},{"key":"6460_CR25","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1093\/oncolo\/oyae120","volume":"29","author":"MC Markowski","year":"2024","unstructured":"Markowski MC, Sternberg CN, Wang H, Wang T, Linville L, Marshall CH et al (2024) TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations. Oncologist 29:794\u2013800. https:\/\/doi.org\/10.1093\/oncolo\/oyae120","journal-title":"Oncologist"},{"key":"6460_CR26","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1038\/s41591-025-03961-8","volume":"31","author":"G Attard","year":"2025","unstructured":"Attard G, Agarwal N, Graff JN, Sandhu S, Efstathiou E, \u00d6zg\u00fcro\u011flu M et al (2025) Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. Nat Med 31:4109\u20134118. https:\/\/doi.org\/10.1038\/s41591-025-03961-8","journal-title":"Nat Med"},{"key":"6460_CR27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2217\/fon-2023-0526","volume":"20","author":"N Agarwal","year":"2024","unstructured":"Agarwal N, Saad F, Azad AA, Mateo J, Matsubara N, Shore ND et al (2024) TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. Future Oncol 20:493\u2013505. https:\/\/doi.org\/10.2217\/fon-2023-0526","journal-title":"Future Oncol"},{"key":"6460_CR28","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","volume":"77","author":"N Matsubara","year":"2020","unstructured":"Matsubara N, Chi KN, \u00d6zg\u00fcro\u011flu M, Rodriguez-Antolin A, Feyerabend S, Fein L et al (2020) Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. Eur Urol 77:494\u2013500. https:\/\/doi.org\/10.1016\/j.eururo.2019.11.021","journal-title":"Eur Urol"},{"key":"6460_CR29","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1001\/jamaoncol.2024.3074","volume":"10","author":"CH Marshall","year":"2024","unstructured":"Marshall CH, Teply BA, Lu J, Oliveira L, Wang H, Mao SS et al (2024) Olaparib without androgen deprivation for high-risk biochemically recurrent prostate cancer following prostatectomy: a nonrandomized controlled trial. JAMA Oncol 10:1400\u20131408. https:\/\/doi.org\/10.1001\/jamaoncol.2024.3074","journal-title":"JAMA Oncol"},{"key":"6460_CR30","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/s1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD et al (2023) Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol 24:1094\u20131108. https:\/\/doi.org\/10.1016\/s1470-2045(23)00382-0","journal-title":"Lancet Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06460-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06460-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06460-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:13:35Z","timestamp":1779768815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06460-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6460"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06460-8","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"21 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"354"}}